Arming oncolytic viruses to leverage antitumor immunity

The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

(2015) Daniel Sanghoon Shin et al.   CURRENT OPINION IN IMMUNOLOGY

Engager T Cells: A New Class of Antigen-specific T Cells That Redirect Bystander T Cells

(2015) Kota Iwahori et al.   MOLECULAR THERAPY

Immunological data from cancer patients treated with Ad5/3 E2F Δ24 GMCSF suggests utility for tumor immunotherapy

(2015) Otto Hemminki et al.   Oncotarget

Retargeted oncolytic adenovirus displaying a single variable domain of camelid heavy-chain-only antibody in a fiber protein

(2015) Elisabeth A van Erp et al.   Molecular Therapy-Oncolytics

An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites

(2015) Xinping Fu et al.   Oncotarget

Expression of CCL19 from Oncolytic Vaccinia Enhances Immunotherapeutic Potential while Maintaining Oncolytic Activity

(2015) Jun Li et al.   NEOPLASIA

Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers

(2014) T Du et al.   CANCER GENE THERAPY

Bispecific antibody platforms for cancer immunotherapy

(2014) Roeland Lameris et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

GMCSF-armed vaccinia virus induces an antitumor immune response

(2014) Suvi Parviainen et al.   INTERNATIONAL JOURNAL OF CANCER

Acquired and intrinsic resistance in cancer immunotherapy

(2014) Sander Kelderman et al.   Molecular Oncology

CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy

(2014) Christine E Engeland et al.   MOLECULAR THERAPY

Giving Oncolytic Vaccinia Virus More BiTE

(2014) Steven M Albelda et al.   MOLECULAR THERAPY

Harnessing the Immune System to Potentiate Oncolytics

(2014) Stephen Gottschalk et al.   MOLECULAR THERAPY

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

(2014) Carsten Linnemann et al.   NATURE MEDICINE

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

(2014) E. Tran et al.   SCIENCE

Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

(2014) D. Zamarin et al.   Science Translational Medicine

Co-Inhibitory Pathways and Their Importance in Immune Regulation

(2014) Naoka Murakami et al.   TRANSPLANTATION

Nanobody: The “Magic Bullet” for Molecular Imaging?

(2014) Rubel Chakravarty et al.   Theranostics

Oncolytic Viruses and Their Application to Cancer Immunotherapy

(2014) E. A. Chiocca et al.   Cancer Immunology Research

Armed Therapeutic Viruses – A Disruptive Therapy on the Horizon of Cancer Immunotherapy

(2014) Maxine Bauzon et al.   Frontiers in Immunology

Trial Watch:

(2014) Jonathan Pol et al.   OncoImmunology

Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)

(2014) Robert HI Andtbacka et al.   Journal for ImmunoTherapy of Cancer

Oncolytic Virus-Mediated Reversal of Impaired Tumor Antigen Presentation

(2014) Shashi A. Gujar et al.   Frontiers in Oncology

Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1

(2014) Markus Moehler et al.   Frontiers in Oncology

Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity

(2014) Zong Sheng Guo et al.   Frontiers in Oncology

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

(2013) P. A. Ott et al.   CLINICAL CANCER RESEARCH

Current status of gene therapy for cancer

(2013) Wolfgang Walther et al.   CURRENT OPINION IN ONCOLOGY

The tumor microenvironment at a glance

(2013) F. R. Balkwill et al.   JOURNAL OF CELL SCIENCE

Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma

(2013) Nienke van Rooij et al.   JOURNAL OF CLINICAL ONCOLOGY

Oncolytic viruses as therapeutic cancer vaccines

(2013) David L Bartlett et al.   Molecular Cancer

Multifaceted Therapeutic Targeting of Ovarian Peritoneal Carcinomatosis Through Virus-induced Immunomodulation

(2013) Shashi Gujar et al.   MOLECULAR THERAPY

T-cell Engager-armed Oncolytic Vaccinia Virus Significantly Enhances Antitumor Therapy

(2013) Feng Yu et al.   MOLECULAR THERAPY

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

(2013) Jeong Heo et al.   NATURE MEDICINE

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

(2013) Paul F Robbins et al.   NATURE MEDICINE

Oncolytic and Immunotherapeutic Vaccinia Induces Antibody-Mediated Complement-Dependent Cancer Cell Lysis in Humans

(2013) M. K. Kim et al.   Science Translational Medicine

Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy

(2013) Christel Devaud et al.   OncoImmunology

Functional characterization of a STAT3-dependent dendritic cell-derived CD14+cell population arising upon IL-10-driven maturation

(2013) Jelle J. Lindenberg et al.   OncoImmunology

Trial watch

(2013) Erika Vacchelli et al.   OncoImmunology

Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment

(2012) Douglas Hanahan et al.   CANCER CELL

Targeting the Tumor Microenvironment for Cancer Therapy

(2012) N. E. Sounni et al.   CLINICAL CHEMISTRY

The extracellular matrix: A dynamic niche in cancer progression

(2012) Pengfei Lu et al.   JOURNAL OF CELL BIOLOGY

Viral interference with antigen presentation: Trapping TAP

(2012) Maaike E. Ressing et al.   MOLECULAR IMMUNOLOGY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Bispecific antibodies engage T cells for antitumor immunotherapy

(2011) Bryan D Choi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4

(2011) J D Dias et al.   GENE THERAPY

Measles virus causes immunogenic cell death in human melanoma

(2011) O G Donnelly et al.   GENE THERAPY

Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients

(2011) Mari Raki et al.   JOURNAL OF GENE MEDICINE

Vesicular Stomatitis Virus Oncolytic Treatment Interferes with Tumor-Associated Dendritic Cell Functions and Abrogates Tumor Antigen Presentation

(2011) S. Leveille et al.   JOURNAL OF VIROLOGY

Human Adenovirus Type 5 Induces Cell Lysis through Autophagy and Autophagy-Triggered Caspase Activity

(2011) H. Jiang et al.   JOURNAL OF VIROLOGY

Chemokine Expression From Oncolytic Vaccinia Virus Enhances Vaccine Therapies of Cancer

(2011) Jun Li et al.   MOLECULAR THERAPY

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

(2011) G. L. Beatty et al.   SCIENCE

Adenoviruses induce autophagy to promote virus replication and oncolysis

(2011) Humberto Rodriguez-Rocha et al.   VIROLOGY

Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation

(2010) Fabian Benencia et al.   CANCER BIOLOGY & THERAPY

Matrix Metalloproteinases: Regulators of the Tumor Microenvironment

(2010) Kai Kessenbrock et al.   CELL

Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity

(2010) Jelle J Lindenberg et al.   Immunotherapy

Approval of Provenge Seen As First Step for Cancer Treatment Vaccines

(2010) V. Brower   JNCI-Journal of the National Cancer Institute

Reovirus Virotherapy Overrides Tumor Antigen Presentation Evasion and Promotes Protective Antitumor Immunity

(2010) S. A. Gujar et al.   MOLECULAR CANCER THERAPEUTICS

Landmark approval for Dendreon's cancer vaccine

(2010) Laura DeFrancesco   NATURE BIOTECHNOLOGY

Antitumoral Immune Response by Recruitment and Expansion of Dendritic Cells in Tumors Infected with Telomerase-Dependent Oncolytic Viruses

(2009) Edukulla Ramakrishna et al.   CANCER RESEARCH

Interference of CD40L-Mediated Tumor Immunotherapy by Oncolytic Vesicular Stomatitis Virus

(2009) Feorillo Galivo et al.   HUMAN GENE THERAPY

Targeting the Intratumoral Dendritic Cells by the Oncolytic Adenoviral Vaccine Expressing RANTES Elicits Potent Antitumor Immunity

(2009) Natalia Lapteva et al.   JOURNAL OF IMMUNOTHERAPY

Novel Immunocompetent Murine Tumor Model for Evaluation of Conditionally Replication-Competent (Oncolytic) Murine Adenoviral Vectors

(2009) M. Robinson et al.   JOURNAL OF VIROLOGY

Attraction and Activation of Dendritic Cells at the Site of Tumor Elicits Potent Antitumor Immunity

(2009) Natalia Lapteva et al.   MOLECULAR THERAPY

Therapeutic and Tumor-specific Immunity Induced by Combination of Dendritic Cells and Oncolytic Adenovirus Expressing IL-12 and 4-1BBL

(2009) Jing-Hua Huang et al.   MOLECULAR THERAPY

Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy

(2009) A. Frentzen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficient Cross-presentation Depends on Autophagy in Tumor Cells

(2008) Y. Li et al.   CANCER RESEARCH

A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients

(2008) J-L Li et al.   GENE THERAPY

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE